加载中
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
收盘时
US$1.08
−US$0.03 · -2.70%
盘后
US$1.08
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日内区间
当前US$1.08
52周区间
当前US$1.08
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
90
深度低估
情绪
55
多空交织
风险
75
高风险
动量
28
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日内区间
当前US$1.08
52周区间
当前US$1.08
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8027.5万 USD | 6930万 USD | 5845.3万 USD | 4141.8万 USD | 2946.3万 USD |
| 销货成本 | 2593.4万 USD | 2281.2万 USD | 1834.1万 USD | 1437.4万 USD | 1065万 USD |
| 毛利 | 5434.1万 USD | 4648.8万 USD | 4011.2万 USD | 2704.4万 USD | 1881.3万 USD |
| 研究与开发 | 922万 USD | 881.3万 USD | 961.9万 USD | 893.7万 USD | 674.3万 USD |
| 销售、一般及管理费用 | 7887.6万 USD | 7937万 USD | 7456.8万 USD | 5711.4万 USD | 4152.1万 USD |
| 营业费用 | 8809.6万 USD | 8060.3万 USD | 8418.7万 USD | 6605.1万 USD | 4826.4万 USD |
| 利息支出 | 524.5万 USD | 529万 USD | 522.3万 USD | 405.1万 USD | 359.7万 USD |
| 折旧和摊销 | 101万 USD | 101.2万 USD | 80.8万 USD | 118.7万 USD | 53.5万 USD |
| 营业利润 | −3375.5万 USD | −3411.5万 USD | −4407.5万 USD | −3900.7万 USD | −2945.1万 USD |
| 净利润 | −3883.1万 USD | −3784.1万 USD | −4666.4万 USD | −4429.6万 USD | −3327.6万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.00
上涨空间 85.19%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
